drugset
drugset / Trial / NCT06070857

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers

NCT06070857 ↗

Phase 1 Completed 81 enrolled Vigonvita Life Sciences
RandomizedParallel-groupTriple-blindTreatment

Summary

The study consists of 10 dose groups, 8 subjects in each group (male or female), randomly assigned to study drug or placebo group to evaluate the safety, tolerability and pharmacokinetics characteristics.

Timeline

Start
2023-10-05
Primary completion
2025-11-17
Completion
2025-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject LV232 Unknown 1 mg Oral
Subject LV232 Unknown 2 mg Oral
Subject LV232 Unknown 4 mg Oral
Subject LV232 Unknown 8 mg Oral
Subject LV232 Unknown 15 mg Oral
Subject LV232 Unknown 25 mg Oral
Subject LV232 Unknown 40 mg Oral
Subject LV232 Unknown 60 mg Oral
Subject LV232 Unknown 90 mg Oral
Subject LV232 Unknown 120 mg Oral

Indications

No indication recorded.